Caricamento...
The Why, what, and How of the New FACT standards for immune effector cells
Novel cellular therapies outside of traditional hematopoietic stem cell transplantation or hematopoietic progenitor cell (HPC) therapy are currently under evaluation in clinical trials across the United States and around the world. Several cellular products, e.g., CD19-directed Chimeric Antigen Rece...
Salvato in:
| Pubblicato in: | J Immunother Cancer |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5394615/ https://ncbi.nlm.nih.gov/pubmed/28428885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0239-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|